Q5152 Injection, eculizumab-aeeb, 2 milligrams
Also known as: eculizumab biosimilar, C5 inhibitor, complement inhibitor
Injection of eculizumab-aeeb (Fabhalta), a biosimilar to eculizumab, administered at 2 milligrams per dose.
In Plain Language
rare blood disorder treatment; immune system regulator; complement cascade blocker
Clinical Context
Used for atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria management. Blocks complement component 5 activation and administration is intravenous.
RVU Information
CPT Q5152 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5152?
CPT Q5152 (Injection, eculizumab-aeeb, 2 milligrams) is a Q Codes code. Injection of eculizumab-aeeb (Fabhalta), a biosimilar to eculizumab, administered at 2 milligrams per dose.
Is Q5152 covered by insurance?
Q5152 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria management. Blocks complement component 5 activation and administration is intravenous.
When is CPT Q5152 used?
Used for atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria management. Blocks complement component 5 activation and administration is intravenous.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.